Want to see EXEL full AI Analyst Report?
EXEL Stock Chart & Stats
$56.72
-$0.28(-0.50%)
At close: 4:00 PM EDT
$56.72
-$0.28(-0.50%)
Day’s Range― - ―
52-Week Range$34.63 - $64.42
Previous CloseN/A
Volume1.84M
Average Volume (3M)2.23M
Market Cap
$15.53B
Enterprise Value$13.83B
Total Cash (Recent Filing)$839.38M
Total Debt (Recent Filing)$165.93M
Price to Earnings (P/E)19.6
Beta0.92
Next Earnings
Oct 29, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding247,781,700
10 Day Avg. Volume2,625,593
30 Day Avg. Volume2,234,625
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit5.88
Enterprise Value/Ebitda13.21
Forecast
1Y Price Target
$53.45Price Target Upside-5.76% Downside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)3.56
Revenue Forecast (FY)$2.55B
Bulls Say, Bears Say
Bulls Say
Market PositionLeading share and faster prescription growth indicate CABOMETYX remains well positioned in core oncology markets, supporting durable demand and commercial resilience. A larger patient and prescriber base also gives Exelixis a platform for expanding indications and funding pipeline development.
Profitability And Cash GenerationStrong profitability and cash conversion provide internal funding for clinical development, commercialization, and business development without relying heavily on external capital. This financial capacity increases strategic flexibility and helps Exelixis absorb development volatility while preserving investment in future growth.
Patent ProtectionThe appellate patent victory extends effective U.S. exclusivity for a key product and reduces the near-term risk of generic competition. Protecting the commercial franchise supports revenue durability, cash generation, and the company’s ability to finance its expanding oncology pipeline.
Bears Say
Slower NET GrowthThe slower NET ramp shows that expansion beyond established indications may take longer than anticipated, reducing near-term growth contribution from the franchise. Patient kinetics, less frequent scanning, and delayed treatment initiation could continue to make adoption uneven across this heterogeneous market.
Higher Gross-to-Net DeductionsHigher gross-to-net deductions reduce the revenue retained from each dollar of product demand, creating pressure on realized sales and margins. If elevated deductions persist, Exelixis may need stronger prescription growth to offset the impact, limiting operating leverage from its commercial franchise.
Zanzalintinib Approval DelayThe delayed regulatory decision postpones potential commercialization of zanzalintinib with atezolizumab in metastatic colorectal cancer. That defers a potential diversification and growth catalyst, while the major-amendment review indicates additional safety or efficacy information must be considered before approval.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $34.63 and its highest was $64.42 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $15.53B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 05, 2026. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.853 by $0.057.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.88.
How many shares outstanding does Exelixis have?
Exelixis has 247,781,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.91 in its last earnings report, beating expectations of $0.853. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$53.45 (-5.76% Downside)
$53.45 (-5.76% Downside)
Blogger Sentiment
Bullish
EXEL Sentiment 60%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 436.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.42%
12-Months-Change
Fundamentals
Return on Equity
42.49%
Trailing 12-Months
Asset Growth
-6.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EXEL Company Deck
EXEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects strong commercial performance, healthy profitability and a well-advanced zanzalintinib development program with multiple pivotal trials and a pending NDA/PDUFA. These positive fundamentals are tempered by a modestly slower-than-expected NET ramp that prompted a $50 million downward adjustment to revenue guidance, higher gross-to-net expectations (30%–31%), and some clinical/regulatory uncertainties (STELLAR-303 subgroup result, 505(b)(2) dynamics). On balance, the company’s execution, cash position (~$1.4B), active share repurchases, and deep pipeline milestones outweigh the near-term headwinds, supporting a constructive outlook while acknowledging short-term risks.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$53.45
▼(-5.76% Downside)
Technical Analysis
Ownership Overview
3.57% Insiders
26.42% Mutual Funds
1.12% Other Institutional Investors
38.19% Public Companies and
Individual Investors